SEC Filing Summary
Filing identification: The provided Form 10-K is for Neuralstem, Inc., not Palisade Bio, Inc. It covers the fiscal year ended December 31, 2013; quarterly data includes the fourth quarter of 2013.
Business Context and Reporting Period
Neuralstem is a development-stage biopharmaceutical company focused on human neural stem-cell therapies and small-molecule compounds for central nervous system diseases. Its lead programs were NSI-566 for ALS, chronic spinal cord injury and ischemic-stroke motor deficits, and NSI-189 for major depressive disorder. The company had no product sales and all principal programs remained in preclinical or clinical development.
- NSI-566 ALS program: Phase II commenced in September 2013; dosing was expected to be completed in the second quarter of 2014.
- NSI-566 stroke program in China: combined Phase I/II/III trial commenced during the fourth quarter of 2013 and was designed to enroll up to 118 patients.
- NSI-566 chronic spinal cord injury: FDA approval obtained; trial expected to commence in 2014.
- NSI-189: Phase Ia completed and Phase Ib dosing completed; data was under review and the company was seeking a development partner.
Financial Performance and Position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $110,000 | $407,708 |
| Operating expenses | $12.634 million | $10.564 million |
| Operating loss | $12.524 million | $10.156 million |
| Net loss | $19.832 million | $10.122 million |
| Net loss per share | $0.27 | $0.17 |
| Net cash used in operating activities | $10.592 million | $8.478 million |
| Cash and cash equivalents at year-end | $16.846 million | $7.444 million |
| Working capital | $11.683 million | $5.896 million |
| Total stockholders’ equity | $8.418 million | $6.973 million |
- Revenue consisted primarily of $110,000 from licensing intellectual property; there were no product-sale revenues.
- Research and development expense increased 17% to $7.134 million, reflecting higher clinical-trial, laboratory, personnel, travel and share-based compensation costs.
- General and administrative expense increased 24% to $5.255 million, primarily due to higher professional services, share-based compensation, insurance and charitable contributions.
- FY 2013 net loss included $5.017 million of warrant modification expense, $1.394 million of interest expense and a $965,000 loss from changes in the fair value of derivative instruments.
- Share-based compensation expense was $2.331 million, compared with $1.611 million in 2012.
Liquidity, Cash Flow and Debt
- Cash increased by $9.402 million during 2013, primarily because of $20.525 million in financing cash inflows, partially offset by operating and investing cash use.
- Financing proceeds included approximately $7.551 million of net long-term debt proceeds, $7.049 million from common-stock and warrant offerings, and $6.108 million from warrant exercises.
- Outstanding debt had approximately $8.0 million of principal at December 31, 2013. The debt was secured by substantially all company assets, including intellectual property, bore interest at a variable rate with an 11% floor, and matured in June 2016.
- Principal payments under the debt were approximately $2.940 million in 2014, $3.280 million in 2015 and $1.780 million in 2016. Monthly principal and interest payments of approximately $300,000 began in January 2014.
- Management reported monthly operating cash burn of approximately $900,000 and expected existing cash, anticipated income and expected financing proceeds to fund current activities through at least December 31, 2014, subject to potential reductions in activities and personnel.
- In January 2014, after year-end, the company raised approximately $20 million in gross proceeds through a registered direct offering of common stock and warrants.
Material Changes Versus the Prior Comparable Period
- Revenue declined approximately 73% because the Department of Defense subcontract ended in 2012; 2013 revenue was limited to intellectual-property licensing.
- Operating expenses increased approximately 20%, with both research and development and general and administrative costs rising.
- Net loss nearly doubled, primarily because of warrant modification expense, higher interest expense and derivative fair-value losses.
- Operating cash use increased 25% as clinical-trial and research activities expanded.
- Cash and working capital improved substantially from equity, warrant-exercise and debt financing, but leverage and required debt service were new material obligations.
- Common shares outstanding increased from 68.2 million at year-end 2012 to 77.9 million at year-end 2013, with substantial additional dilution possible from outstanding options and warrants.
Guidance, Outlook, Risks and Unusual Items
Management did not provide conventional revenue or earnings guidance. The stated near-term priorities were advancing clinical trials, initiating the chronic spinal cord injury program, pursuing additional preclinical work and seeking a partner for NSI-189. The company stated that it did not expect to be profitable in the next several years.
- The business is dependent on additional capital because it has a history of losses, approximately $128.4 million of accumulated deficit at year-end 2013 and no commercial product revenue.
- Clinical outcomes, regulatory approvals, manufacturing scale-up and market acceptance remain uncertain. Positive early-stage results may not predict later-stage success.
- Stem-cell and small-molecule manufacturing was substantially outsourced to Charles River Laboratories and AMRI, creating supplier, quality-control and regulatory risks.
- Substantially all assets, including intellectual property, secured the company’s debt. Failure to make payments or comply with covenants could trigger acceleration and foreclosure remedies.
- The company disclosed ongoing patent litigation with StemCells, Inc.; the proceedings were stayed pending resolution of standing issues, and the ultimate outcome was unknown.
- The company held approximately $82.0 million of federal net operating loss carryforwards, but maintained a full valuation allowance because realization was not considered more likely than not.
- The independent auditor reported that the financial statements were fairly presented under U.S. GAAP and that internal control over financial reporting was effective as of December 31, 2013.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Neuralstem, Inc., whereas the request identifies Palisade Bio, Inc.
- Verify the terms, covenants, collateral and amortization schedule of the approximately $8 million secured debt.
- Assess whether the January 2014 $20 million financing and subsequent warrant exercises materially changed liquidity and dilution.
- Review clinical-trial progress, enrollment, safety results and regulatory status for NSI-566 and NSI-189.
- Evaluate the potential financial impact and current status of the StemCells patent litigation.
- Reconcile outstanding options, warrants and derivative liabilities with the potential dilution to common shareholders.